News > Syngene to acquire multi-modal facility from Stelis Biopharma Ltd, adding 20,000 litres of installed biologics drug substance manufacturing capacity, with scope for further expansion, and a high speed, commercial scale, fill-finish unit

Syngene to acquire multi-modal facility from Stelis Biopharma Ltd, adding 20,000 litres of installed biologics drug substance manufacturing capacity, with scope for further expansion, and a high speed, commercial scale, fill-finish unit

Syngene today announced the acquisition of Unit 3 biologics manufacturing facility in Bangalore, India, from Stelis Biopharma Limited (SBL). The companies have entered into a binding term sheet and, on completion of the transaction, the site will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene. The site has the potential for future expansion up to a further 20,000 litres of biologics drug substance manufacturing capacity.